Literature DB >> 15247170

Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.

M Solaymani-Dodaran1, R F A Logan, J West, T Card, C Coupland.   

Abstract

BACKGROUND AND AIMS: While patients with Barrett's oesophagus develop oesophageal adenocarcinoma more frequently than the general population, it has controversially been suggested that gastro-oesophageal reflux (GORD) itself is a more important determinant of risk. In order to assess the validity of this suggestion, we examined the risk of oesophageal cancer in patients with Barrett's and with GORD compared with the general population in a community based cohort study.
METHODS: Cohorts of patients with Barrett's (n = 1677), oesophagitis (n = 6392), and simple reflux (n = 6328), and a reference cohort (n = 13416) were selected from the General Practice Research Database. The last three cohorts were matched to the Barrett's cohort by general practitioner practice, age, and sex. Cox's regression analysis was used to calculate relative risks for oesophageal cancer. Standardised incidence ratio methodology was used to estimate the relative risks for oesophageal adenocarcinoma.
RESULTS: A total of 137 oesophageal cancers were identified, of which 94 prevalent cases were excluded. The hazard ratios for oesophageal cancer were 10.6 (5.1-22.0), 2.2 (0.9-5.2), and 1.7 (0.7-4.5) in the Barrett's, oesophagitis, and reflux cohorts compared with the reference cohort, respectively. The corresponding relative risks for oesophageal adenocarcinoma were 29.8 (9.6-106), 4.5 (1.04-19.6), and 3.1 (0.6-14.2).
CONCLUSION: Barrett's oesophagus increases the risk of oesophageal cancer approximately 10 times and oesophageal adenocarcinoma approximately 30 times compared with the general population. There is only a modestly increased risk of oesophageal cancer in patients with reflux who have no record of Barrett's oesophagus. Our findings therefore do not support the suggestion that gastro-oesophageal reflux disease itself predisposes to cancer.

Entities:  

Mesh:

Year:  2004        PMID: 15247170      PMCID: PMC1774141          DOI: 10.1136/gut.2003.028076

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  40 in total

1.  The significance of heartburn.

Authors:  B T Johnston
Journal:  QJM       Date:  2000-06

Review 2.  Is there publication bias in the reporting of cancer risk in Barrett's esophagus?

Authors:  N J Shaheen; M A Crosby; E M Bozymski; R S Sandler
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

3.  Risk of adenocarcinoma in Barrett's oesophagus: population based study.

Authors:  Liam Murray; Peter Watson; Brian Johnston; James Sloan; Inder Mohan Lal Mainie; Anna Gavin
Journal:  BMJ       Date:  2003-09-06

4.  Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation.

Authors:  V F Eckardt; G Kanzler; G Bernhard
Journal:  Am J Med       Date:  2001-07       Impact factor: 4.965

5.  Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries.

Authors:  A A Botterweck; L J Schouten; A Volovics; E Dorant; P A van Den Brandt
Journal:  Int J Epidemiol       Date:  2000-08       Impact factor: 7.196

6.  Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.

Authors:  A P Weston; A S Badr; R S Hassanein
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

7.  Correlation of oesophageal acid exposure with Barrett's oesophagus length.

Authors:  R Fass; R W Hell; H S Garewal; P Martinez; G Pulliam; C Wendel; R E Sampliner
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

8.  Adenocarcinoma and Barrett's esophagus. An overrated risk?

Authors:  S J Spechler; A H Robbins; H B Rubins; M E Vincent; T Heeren; W G Doos; T Colton; E M Schimmel
Journal:  Gastroenterology       Date:  1984-10       Impact factor: 22.682

9.  Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease.

Authors:  James D Lewis; Colleen Brensinger; Warren B Bilker; Brian L Strom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Apr-May       Impact factor: 2.890

10.  Socioeconomic status and risk of adenocarcinoma of the oesophagus and cancer of the gastric cardia in Scotland.

Authors:  D H Brewster; L A Fraser; P A McKinney; R J Black
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

View more
  87 in total

1.  Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis.

Authors:  Deirdre P Cronin-Fenton; Liam J Murray; David C Whiteman; Chris Cardwell; Penelope M Webb; Susan J Jordan; Douglas A Corley; Linda Sharp; Jesper Lagergren
Journal:  Eur J Cancer       Date:  2010-04-22       Impact factor: 9.162

2.  Oesophageal cancer and gastro-oesophageal reflux: what is the relationship?

Authors:  J Lagergren
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

3.  Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.

Authors:  Panteleimon Kountourakis; Jaffer A Ajani; Marta Davila; Jeffrey H Lee; Manoop S Bhutani; Julie G Izzo
Journal:  Gastrointest Cancer Res       Date:  2012-03

4.  Label-free multi-photon imaging of dysplasia in Barrett's esophagus.

Authors:  Soroush Mehravar; Bhaskar Banerjee; Hemant Chatrath; Babak Amirsolaimani; Krunal Patel; Charmi Patel; Robert A Norwood; Nasser Peyghambarian; Khanh Kieu
Journal:  Biomed Opt Express       Date:  2015-12-16       Impact factor: 3.732

Review 5.  Endoscopic therapy for Barrett's oesophagus.

Authors:  H Barr; N Stone; B Rembacken
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

6.  The risk of oesophageal adenocarcinoma in a prospectively recruited Barrett's oesophagus cohort.

Authors:  B T Theron; H Padmanabhan; H Aladin; P Smith; E Campbell; P Nightingale; B T Cooper; N J Trudgill
Journal:  United European Gastroenterol J       Date:  2016-02-19       Impact factor: 4.623

7.  Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.

Authors:  Cathy Bennett; Nimish Vakil; Jacques Bergman; Rebecca Harrison; Robert Odze; Michael Vieth; Scott Sanders; Laura Gay; Oliver Pech; Gaius Longcroft-Wheaton; Yvonne Romero; John Inadomi; Jan Tack; Douglas A Corley; Hendrik Manner; Susi Green; David Al Dulaimi; Haythem Ali; Bill Allum; Mark Anderson; Howard Curtis; Gary Falk; M Brian Fennerty; Grant Fullarton; Kausilia Krishnadath; Stephen J Meltzer; David Armstrong; Robert Ganz; Gianpaolo Cengia; James J Going; John Goldblum; Charles Gordon; Heike Grabsch; Chris Haigh; Michio Hongo; David Johnston; Ricky Forbes-Young; Elaine Kay; Philip Kaye; Toni Lerut; Laurence B Lovat; Lars Lundell; Philip Mairs; Tadakuza Shimoda; Stuart Spechler; Stephen Sontag; Peter Malfertheiner; Iain Murray; Manoj Nanji; David Poller; Krish Ragunath; Jaroslaw Regula; Renzo Cestari; Neil Shepherd; Rajvinder Singh; Hubert J Stein; Nicholas J Talley; Jean-Paul Galmiche; Tony C K Tham; Peter Watson; Lisa Yerian; Massimo Rugge; Thomas W Rice; John Hart; Stuart Gittens; David Hewin; Juergen Hochberger; Peter Kahrilas; Sean Preston; Richard Sampliner; Prateek Sharma; Robert Stuart; Kenneth Wang; Irving Waxman; Chris Abley; Duncan Loft; Ian Penman; Nicholas J Shaheen; Amitabh Chak; Gareth Davies; Lorna Dunn; Yngve Falck-Ytter; John Decaestecker; Pradeep Bhandari; Christian Ell; S Michael Griffin; Stephen Attwood; Hugh Barr; John Allen; Mark K Ferguson; Paul Moayyedi; Janusz A Z Jankowski
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

8.  Have patients with esophagitis got an increased risk of adenocarcinoma? Results from a population-based study.

Authors:  Seamus J Murphy; Lesley A Anderson; Brian T Johnston; Deirdre A Fitzpatrick; Peter Rg Watson; Pauline Monaghan; Liam J Murray
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

9.  Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.

Authors:  Aaron P Thrift; Lesley A Anderson; Liam J Murray; Michael B Cook; Nicholas J Shaheen; Joel H Rubenstein; Hashem B El-Serag; Thomas L Vaughan; Jennifer L Schneider; David C Whiteman; Douglas A Corley
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

Review 10.  Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways.

Authors:  Aaron J Schetter; Niels H H Heegaard; Curtis C Harris
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.